Patent · US Active

Antibody capable of specifically recognizing transferrin receptor

US9598496B2 · kind B2 · utility

11Cited by
0References
36Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMay 7, 2012
Grant dateMar 21, 2017
Priority date
Expiry dateMay 7, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K16/2881
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.